202 related articles for article (PubMed ID: 29454317)
1. Oxidative damage and response to Bacillus Calmette-Guérin in bladder cancer cells expressing sialyltransferase ST3GAL1.
Severino PF; Silva M; Carrascal M; Malagolini N; Chiricolo M; Venturi G; Barbaro Forleo R; Astolfi A; Catera M; Videira PA; Dall'Olio F
BMC Cancer; 2018 Feb; 18(1):198. PubMed ID: 29454317
[TBL] [Abstract][Full Text] [Related]
2. Expression of sialyl-Tn sugar antigen in bladder cancer cells affects response to
Severino PF; Silva M; Carrascal M; Malagolini N; Chiricolo M; Venturi G; Astolfi A; Catera M; Videira PA; Dall'Olio F
Oncotarget; 2017 Aug; 8(33):54506-54517. PubMed ID: 28903359
[TBL] [Abstract][Full Text] [Related]
3. Effect of different Bacillus Calmette-Guerin substrains on growth inhibition of T24 bladder cancer cells and cytokines secretion by BCG activated peripheral blood mononuclear cells of PBMCs.
Janaszek-Seydlitz W; Prygiel M; Bucholc B; Wiatrzyk A; Czajka U; Górska P; Soliwoda U
Adv Clin Exp Med; 2014; 23(6):877-84. PubMed ID: 25618112
[TBL] [Abstract][Full Text] [Related]
4. Breaking Barriers: Modulation of Tumor Microenvironment to Enhance Bacillus Calmette-Guérin Immunotherapy of Bladder Cancer.
Ibrahim OM; Kalinski P
Cells; 2024 Apr; 13(8):. PubMed ID: 38667314
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of Bacillus Calmette‑Guérin by targeting macrophages against bladder cancer in a NOD/scid IL2Rg‑/‑ mouse model.
Tan QL; Zhou CY; Cheng L; Luo M; Liu CP; Xu WX; Zhang X; Zeng X
Mol Med Rep; 2020 Jul; 22(1):362-370. PubMed ID: 32319653
[TBL] [Abstract][Full Text] [Related]
6. ST3Gal.I sialyltransferase relevance in bladder cancer tissues and cell lines.
Videira PA; Correia M; Malagolini N; Crespo HJ; Ligeiro D; Calais FM; Trindade H; Dall'Olio F
BMC Cancer; 2009 Oct; 9():357. PubMed ID: 19811634
[TBL] [Abstract][Full Text] [Related]
7. Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy.
Lima L; Severino PF; Silva M; Miranda A; Tavares A; Pereira S; Fernandes E; Cruz R; Amaro T; Reis CA; Dall'Olio F; Amado F; Videira PA; Santos L; Ferreira JA
Br J Cancer; 2013 Oct; 109(8):2106-14. PubMed ID: 24064971
[TBL] [Abstract][Full Text] [Related]
8. TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells.
Olbert PJ; Kesch C; Henrici M; Subtil FS; Honacker A; Hegele A; Hofmann R; Hänze J
Urol Oncol; 2015 Mar; 33(3):110.e19-27. PubMed ID: 25499923
[TBL] [Abstract][Full Text] [Related]
9. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
10. Effect of nitric oxide inhibition in Bacillus Calmette-Guerin bladder cancer treatment.
Langle YV; Balarino NP; Belgorosky D; Cresta Morgado PD; Sandes EO; Marino L; Bilbao ER; Zambrano M; Lodillinsky C; Eiján AM
Nitric Oxide; 2020 May; 98():50-59. PubMed ID: 32147582
[TBL] [Abstract][Full Text] [Related]
11. The role of cancer stem cells in immunotherapy for bladder cancer: An in vitro study.
Özcan Y; Çağlar F; Celik S; Demir AB; Erçetin AP; Altun Z; Aktas S
Urol Oncol; 2020 May; 38(5):476-487. PubMed ID: 32192892
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
[TBL] [Abstract][Full Text] [Related]
13. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.
Luo Y; Yamada H; Chen X; Ryan AA; Evanoff DP; Triccas JA; O'Donnell MA
Clin Exp Immunol; 2004 Jul; 137(1):24-34. PubMed ID: 15196240
[TBL] [Abstract][Full Text] [Related]
15. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
Lim CJ; Nguyen PHD; Wasser M; Kumar P; Lee YH; Nasir NJM; Chua C; Lai L; Hazirah SN; Loh JJH; Khor LY; Yeong J; Lim TKH; Low AWX; Albani S; Chong TW; Chew V
Front Immunol; 2020; 11():615091. PubMed ID: 33584702
[TBL] [Abstract][Full Text] [Related]
16. Identification and Biochemical Characterization of the Novel α2,3-Sialyltransferase WbwA from Pathogenic Escherichia coli Serotype O104.
Czuchry D; Desormeaux P; Stuart M; Jarvis DL; Matta KL; Szarek WA; Brockhausen I
J Bacteriol; 2015 Dec; 197(24):3760-8. PubMed ID: 26391208
[TBL] [Abstract][Full Text] [Related]
17. The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells.
Cho MJ; Kim MJ; Kim K; Choi YW; Lee SJ; Whang YM; Chang IH
Biochem Biophys Res Commun; 2019 Jan; 509(1):167-174. PubMed ID: 30579607
[TBL] [Abstract][Full Text] [Related]
18. BCG response prediction with cytokine gene variants and bladder cancer: where we are?
Ahirwar DK; Manchanda PK; Mittal RD; Bid HK
J Cancer Res Clin Oncol; 2011 Dec; 137(12):1729-38. PubMed ID: 21932129
[TBL] [Abstract][Full Text] [Related]
19. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
